Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage live biotherapeutics company that regularly issues news about its microbiome-based drug programs, regulatory interactions, and corporate developments. The company focuses on oral live biotherapeutics for medically vulnerable patient populations, particularly adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) and other high-risk groups.
News about Seres often centers on its lead investigational candidate SER-155, including Phase 1b clinical data showing a significant reduction in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia in allo-HSCT patients compared with placebo. Updates also cover regulatory designations for SER-155, such as Breakthrough Therapy and Fast Track status, and detailed feedback from the U.S. Food and Drug Administration on the design of a planned Phase 2 study.
Investors and followers of MCRB can expect announcements on clinical trial progress, investigator-sponsored studies in areas like immune checkpoint inhibitor–related enterocolitis, and research presentations at major medical meetings. Seres also issues press releases on mechanistic publications for its live biotherapeutics, including VOWST™, and on data generated from its MbTx® platform that support its broader live biotherapeutic strategy.
In addition to R&D updates, Seres publishes news on cost-reduction actions, cash runway expectations, leadership changes, and efforts to secure capital or partnerships to advance its pipeline. For those tracking MCRB, this news feed provides a centralized view of program milestones, scientific data, regulatory interactions, and corporate actions that shape the company’s live biotherapeutics portfolio.
On April 5, 2023, Seres Therapeutics (Nasdaq: MCRB) announced the granting of inducement equity awards totaling 22,000 shares to three new employees. This includes options for 11,000 shares and restricted stock units (RSUs) for another 11,000 shares. The stock options have an exercise price of $5.61 per share and will vest over a specified schedule, rewarding employees for their service. This grant is part of the 2022 Employment Inducement Award Plan, which allows the company to incentivize new employees under Nasdaq rules. This announcement is part of Seres' strategy to attract and retain talent in the competitive biotech sector, enhancing its operational capacity to develop microbiome therapeutics.
Seres Therapeutics, a leading microbiome therapeutics company (Nasdaq: MCRB), announced that CEO Eric Shaff will present at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 8:40 a.m. ET. The presentation will be accessible via an audio webcast on Seres' website, with a replay available for 21 days after the event.
Seres is pioneering novel multifunctional bacterial consortia aimed at treating diseases. Its SER-109 program has achieved positive clinical results, gaining FDA Breakthrough Therapy and Orphan Drug designations for preventing recurrent C. difficile infections. The company is also advancing SER-155 in a Phase 1b study targeting gastrointestinal infections and other conditions.
Seres Therapeutics (MCRB) reported its 2022 financials and business updates, highlighting the FDA's review of its SER-109 Biologics License Application, with a target decision date of April 26, 2023. SER-109 is an oral microbiome therapeutic aimed at recurrent C. difficile infection (rCDI), showing an 88% success rate in preventing recurrence in trials. Commercial launch is expected soon after FDA approval. The company also advances SER-155, with preliminary data expected in May 2023. Despite a significant net loss of $250.2 million in 2022, Seres anticipates a $125 million milestone payment upon SER-109's approval.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced on March 1, 2023, the grant of inducement equity awards totaling 15,500 shares to three new employees. The awards comprise 9,250 stock options and 6,250 restricted stock units (RSUs), issued under the Company's 2022 Employment Inducement Award Plan.
The options have an exercise price of $5.15 per share and will vest over time, with 25% vesting after one year and the remainder vesting quarterly. This plan aims to attract talent in compliance with Nasdaq rules.
Seres Therapeutics (NASDAQ: MCRB) will host a conference call on March 7, 2023, at 8:30 a.m. ET to discuss its Q4 and full year 2022 results and provide a business update. Interested parties can join the call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 4218669. Seres specializes in microbiome therapeutics and has developed SER-109, which is in the process of advancing as a potential first-in-class oral FDA-approved microbiome therapeutic for C. difficile infection. The company also evaluates SER-155 in Phase 1b studies for patients undergoing stem cell transplants.
Seres Therapeutics (NASDAQ: MCRB) announced that President and CEO Eric Shaff will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 9:10 a.m. ET. An audio webcast will be available on the company’s website under the 'Investors and News' section, with a replay accessible for 21 days after the event.
Seres is a leader in microbiome therapeutics, notably advancing the SER-109 program, aimed at preventing C. difficile infection recurrences, with FDA breakthrough designations. The company also evaluates SER-155 for patients undergoing stem cell transplants.
Seres Therapeutics (NASDAQ: MCRB) announced the publication of Phase 3 ECOSPOR IV trial results in JAMA Network Open, showing that 91.3% of subjects were free from recurrent C. difficile infections at 8 weeks. The trial involved 263 participants and also indicated a significant improvement in health-related quality of life compared to placebo. The safety profile was consistent with prior trials, showing no treatment-related withdrawals. A Biologics License Application for SER-109 has been submitted to the FDA, with a PDUFA action date set for April 26, 2023. These results further support the company's efforts in microbiome therapeutics.
Seres Therapeutics (NASDAQ: MCRB) has commenced enrollment for Cohort 2 of its Phase 1b study of SER-155, an oral microbiome therapeutic aimed at reducing gastrointestinal infections and graft versus host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Following a positive review from the Data and Safety Monitoring Board, the company plans to report initial safety and pharmacological data from Cohort 1 in the upcoming months. SER-155's development is based on promising results from the Phase 3 SER-109 program. The company estimates over 9,000 patients receive allo-HSCT annually in the U.S., with significant associated management costs.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced on February 1, 2023 that its Compensation and Talent Committee granted inducement equity awards totaling 48,750 shares to eleven new employees. This includes stock options for 32,500 shares at an exercise price of $5.49 and restricted stock units (RSUs) for 16,250 shares. The equity grants are part of the 2022 Employment Inducement Award Plan adopted in December 2022. The stock options vest incrementally, while RSUs vest annually and quarterly after the first year.
Seres Therapeutics (NASDAQ: MCRB) announced on January 11, 2023, that its Compensation and Talent Committee granted equity awards to five new employees. This consists of 9,000 stock options at an exercise price of $5.26 per share and 4,500 restricted stock units (RSUs). The awards are governed by the Seres 2022 Employment Inducement Award Plan, which was established in December 2022 to attract new talent. Stock options vest over time, starting with 25% after one year of employment. Seres continues to develop innovative microbiome therapeutics aimed at treating diseases through functional interaction with host cells and tissues.